查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919422

犬类癌症筛检市场：按产品类型、技术、癌症类型、检体类型和最终用户划分 - 全球预测（2026-2032 年）

Canine Cancer Screening Market by Product Type, Technology, Cancer Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年犬类癌症筛检市场价值为 3.0597 亿美元，预计到 2026 年将成长至 3.2565 亿美元，预计到 2032 年将达到 4.1936 亿美元，复合年增长率为 4.60%。

关键市场统计数据
基准年 2025 3.0597亿美元
预计年份：2026年 3.2565亿美元
预测年份 2032 4.1936亿美元
复合年增长率 (%) 4.60%

权威的导论阐述了临床需求和诊断技术创新如何融合，从而重新定义犬类癌症筛检的主动方法

诊断技术的进步和临床上对伴侣动物肿瘤学日益增长的兴趣正在重塑兽医实践和研究的重点。过去仅限于健康检查期间机会性检测的筛检模式，正在演变为强调早期发现、微创取样和综合诊断的主动式项目。这些变化反映了技术的成熟和饲主对先进治疗方案日益增长的需求，共同推动了对能够更早、更可靠地检测犬类癌症的工具的投资。

分子诊断技术、生物标记整合和多模态工作流程的进步正在从根本上改变犬类癌症筛检实践和决策。

犬类癌症筛检领域正经历变革性的转变，多种因素共同推动诊断方法的开发、检验和应用方式的改变。新兴的分子平台和定序技术能够精准地表征肿瘤生物学特征，而生物标记检测技术的改进则提高了早期检测的信噪比。这些进步，加上与成像策略的整合以及检体类型的扩展，正在催生出几年前在技术和经济上都难以实现的混合工作流程。

评估进口成本波动和关税导致的供应链变化将如何影响犬类癌症诊断的采购模式、检查室能力和实施时间表。

贸易和关税政策的变化会对兽医诊断设备、试剂和服务的整个供应链产生显着影响。当进口关税和贸易限制导致成像设备、定序平台和特殊试剂的到岸价格波动时，供应商将面临利润空间压缩，并可能考虑推迟资本投资或转向其他供应商。这些采购趋势会产生连锁反应，影响检查室产能、新检测方法的推出时间以及诊断服务的地理覆盖范围。

深度細項分析揭示了产品类型、技术、最终用户、癌症类型和检体模式如何定义不同的开发和商业化路径。

基于细分市场的洞察揭示了诊断创新与临床需求和商业性机会的交汇点。依产品类型划分，市场可分为「仪器」、「试剂盒」及「服务」。仪器类别又细分为「影像仪器」、「分子诊断仪器」和「定序平台」。试剂盒包括“ELISA试剂盒”、“NGS试剂盒”和“PCR试剂”，而服务则包括“合约研究”和“检查室服务”。这种层级结构表明，对平台间互通性和耗材可靠性的投资将决定其普及速度。同时，降低技术壁垒的服务模式可望加速临床应用。

基础设施、监管差异以及关键区域的临床应用趋势如何影响犬类癌症筛检解决方案的实际部署策略

区域趋势影响着筛检项目的可近性、报销模式和实际部署。在美洲，先进的诊断检查室和大规模的专业兽医诊所集中分布，有利于新型检测方法和影像平台的快速应用。同时，区域法规结构和支付方结构也影响采购週期和服务定价。从都市区向区域诊所的过渡需要考虑扩充性、远距离诊断服务和照护现场能力，以确保公平的医疗服务取得。

诊断和兽医技术公司推动差异化和临床应用的关键竞争行动和策略重点

主要企业正透过平台扩展、策略联盟和服务型交付模式相结合的方式，在犬类癌症筛检获取价值。现有企业可能会专注于提昇平台相容性，以支援更广泛的检测项目并降低检查室切换成本。同时，专业诊断服务提供者则专注于开发针对特定癌症类型的高灵敏度检测方法，并力求成为这些适应症的临床参考标准。

为开发人员、检查室营运人员和服务供应商提供切实有效的建议，以加速犬类癌症筛检方案的采用和永续扩展。

产业领导者应优先采取几项策略行动，将诊断创新转化为永续的临床成果。首先，儘早与兽医肿瘤学家和诊断检查室接洽，并明确对其临床实践至关重要的性能标准，以确保产品开发与临床可操作的终点指标保持一致。其次，推行模组化平台设计和可互通的测试格式，以减少检查室在支援不同工作流程和旧有系统时遇到的整合障碍。

本研究采用严谨的混合方法研究，将系统性的二次分析与检验的原始访谈结合，以确保研究结果的可靠性和实践导向。

本研究采用的调查方法结合了系统性的二手资料分析和结构化的原始研究，以确保研究结果的稳健性和可重复性。二手资料分析包括查阅同行评审文献、监管指导文件、专利申请、临床试验註册资料以及製造商的技术规范，以了解技术能力和过往表现。这项桌上研究建立了一个基础性的分类体系，涵盖产品类型、技术、最终用户、癌症类型和检体收集方式，为后续研究奠定了基础。

本概要重点阐述了犬类癌症筛检解决方案成功推广至临床应用的关键机会和实际考量。

总之，犬类癌症筛检领域正处于一个转折点，技术进步、不断变化的临床需求和不断变化的商业性格局交织在一起，为提高早期检测率创造了具体机会。整合生物标记检测、基因检测和标靶成像的多模态诊断路径正逐渐成为提高敏感性和临床效用的最有前景的途径。同时，检体类型选择、检查室能力和区域法规结构等实际因素将决定这些方法应用的速度和范围。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 犬类癌症筛检市场（依产品类型划分）

  • 装置
    • 诊断影像设备
    • 分子装置
    • 定序平台
  • 试剂和试剂盒
    • ELISA试剂盒
    • NGS试剂盒
    • PCR试剂
  • 服务
    • 委託研究
    • 检查服务

9. 犬类癌症筛检市场（依技术划分）

  • 生物标记检测
    • ELISA
    • 免疫组织化学
  • 基因检测
    • 基于PCR的
    • 定序定序
  • 影像诊断
    • CT
    • MRI
    • 超音波
    • X射线
  • 分子诊断
    • 次世代定序（NGS）
    • PCR
    • 定量PCR

第十章 犬类癌症筛检市场（依癌症类型划分）

  • 血管肉瘤
  • 淋巴瘤
  • 乳腺肿瘤
  • 皮肤癌

第十一章 犬类癌症筛检市场（依检体类型划分）

  • 血
  • 细针穿刺
  • 唾液
  • 组织切片检查
  • 尿

第十二章 犬类癌症筛检市场（依最终用户划分）

  • 诊断检查室
    • 临床检查室
    • 参考检验机构
  • 研究所
    • 学术机构
    • 私人研究机构
  • 动物诊所
    • 小动物诊所
    • 专科诊所
  • 兽医诊所
    • 企业医院
    • 独立医院

第十三章 犬类癌症筛检市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 犬类癌症筛检市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国犬类癌症筛检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国犬类癌症筛检市场

第十七章：中国犬类癌症筛检市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Animal Cancer Care and Research, Inc.
  • Anivive Lifesciences, Inc.
  • Biomerieux SA
  • BluePearl Veterinary Partners, LLC
  • Cancan Diagnostics AB
  • Cutting Edge Laser Technologies, LLC
  • Embark Veterinary, Inc.
  • Heska Corporation
  • IDEXX Laboratories, Inc.
  • LiteCure LLC
  • Mars Petcare, Inc.
  • Oncotect, Inc.
  • Pathway Vet Alliance, Inc.
  • PetDx, Inc.
  • Petnostics Ltd.
  • Siemens Healthineers AG
  • Torigen Specialty Pathology, Inc.
  • VetDC, Inc.
  • VetGen, LLC
  • VolitionRx Limited
  • Wuxi AppTec
Product Code: MRR-F14BA1B3431D

The Canine Cancer Screening Market was valued at USD 305.97 million in 2025 and is projected to grow to USD 325.65 million in 2026, with a CAGR of 4.60%, reaching USD 419.36 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 305.97 million
Estimated Year [2026] USD 325.65 million
Forecast Year [2032] USD 419.36 million
CAGR (%) 4.60%

An authoritative introduction outlining how converging clinical demand and diagnostic innovation are redefining proactive canine cancer screening pathways

Advances in diagnostics and the rising clinical attention to oncology in companion animals are reshaping veterinary practice and research priorities. Screening paradigms that were once limited to opportunistic testing during wellness visits are evolving toward proactive programs that emphasize early detection, minimally invasive sampling, and integrated diagnostics. These shifts reflect both technological maturation and greater owner willingness to pursue advanced care, which together are driving investment in tools that can detect cancer earlier and more reliably in dogs.

Concurrently, collaborations across veterinary clinics, diagnostic laboratories, and research institutes are intensifying, creating pathways for faster validation and clinical uptake of novel assays and imaging modalities. Regulatory evolution and growing emphasis on evidence-based veterinary oncology are further reinforcing the need for robust screening solutions. As a result, stakeholders from device manufacturers to laboratory service providers are recalibrating their strategies to support scalable, clinically actionable screening workflows that balance sensitivity, specificity, cost, and ease of implementation.

How advances in molecular diagnostics, biomarker integration, and multimodal workflows are fundamentally changing canine cancer screening practice and decision-making

The landscape of canine cancer screening is undergoing transformative shifts driven by several converging forces that alter how diagnostics are developed, validated, and deployed. Emerging molecular platforms and sequencing capabilities are enabling more precise characterization of tumor biology, while biomarker assay refinement improves the signal-to-noise ratio for early-stage detection. As these technologies advance, integration with imaging strategies and expanded sample-type compatibility is creating hybrid workflows that were not technically or economically viable a few years ago.

In practical terms, this transformation means that veterinary clinicians and diagnostic laboratories can offer multi-modal screening algorithms that combine blood-based biomarkers, fine needle aspirates, and targeted imaging to stratify risk more effectively. The shift toward personalized diagnostic pathways is also encouraging cross-disciplinary collaborations with human oncology research, accelerating knowledge transfer and translational validation. Ultimately, these developments are changing expectations around screening frequency, turnaround times, and the clinical decision points that follow a positive screen, prompting stakeholders to reimagine service delivery models and reimbursement conversations.

Assessing how changing import costs and tariff-driven supply chain shifts may alter procurement patterns, laboratory capacity, and adoption timelines for canine cancer diagnostics

Policy shifts in trade and tariffs can produce measurable consequences across the supply chain for diagnostic instruments, reagents, and service delivery in the veterinary sector. When import duties or trade restrictions alter the landed cost of imaging equipment, sequencing platforms, and specialized reagents, providers face compressed margins and may delay capital purchases or shift to alternate suppliers. These procurement dynamics then cascade, affecting laboratory capacity, adoption timelines for new assays, and the geographic footprint of diagnostic services.

Beyond direct cost implications, tariffs influence strategic sourcing and inventory management. Diagnostic laboratories and manufacturers respond by seeking localized distribution, negotiating longer-term contracts, or qualifying alternative reagent vendors to mitigate exposure. In an environment where veterinary clinics and hospitals are operating with constrained budgets, changes in import economics can also slow adoption of high-cost platforms and encourage incremental upgrades to existing systems. Consequently, resilience planning, supplier diversification, and adaptive pricing strategies become critical components of organizational risk management.

Deep segmentation analysis revealing how product types, technologies, end users, cancer types, and sample modalities define distinct development and commercialization pathways

Segmentation-driven insights reveal where diagnostic innovation intersects with clinical need and commercial opportunity. Based on Product Type, the market spans Instruments, Reagents & Kits, and Services, with Instruments further divided into Imaging Instruments, Molecular Instruments, and Sequencing Platforms, Reagents & Kits encompassing Eliza Kits, NGS Kits, and PCR Reagents, and Services including Contract Research and Laboratory Services. This layered structure indicates that investments in platform interoperability and consumable reliability will dictate adoption velocity, while service models that lower technical barriers can accelerate clinical implementation.

Based on Technology, screening solutions are organized across Biomarker Assays, Genetic Testing, Imaging, and Molecular Diagnostics, with Biomarker Assays further classified as Elisa and Immunohistochemistry, Genetic Testing splitting into PCR Based and Sequencing Based approaches, Imaging covering CT, MRI, Ultrasound, and X-Ray, and Molecular Diagnostics mapping to NGS, PCR, and QPCR. The diversity of technological routes underscores the need for cross-validation studies and standardized result interpretation to build clinician confidence.

Based on End User, engagement channels include Diagnostic Laboratories, Research Institutes, Veterinary Clinics, and Veterinary Hospitals, with Diagnostic Laboratories subdivided into Clinical Laboratories and Reference Laboratories, Research Institutes split between Academic Institutions and Private Research, Veterinary Clinics differentiated by Small Animal Clinics and Specialty Clinics, and Veterinary Hospitals segmented into Corporate Hospitals and Independent Hospitals. Each end-user cohort has distinct procurement criteria, service expectations, and clinical workflows, making tailored go-to-market approaches essential.

Based on Cancer Type, screening strategies vary by disease biology across Hemangiosarcoma, Lymphoma, Mammary Tumors, and Skin Cancer, requiring assay and imaging modality adjustments to optimize sensitivity and specificity. Finally, based on Sample Type, workflows leverage Blood, Fine Needle Aspirate, Saliva, Tissue Biopsy, and Urine, and the choice of sample materially affects assay design, pre-analytical logistics, and client acceptance. Together, these segmentations map the terrain for prioritized product development, clinical validation pathways, and differentiated commercial models.

How regional infrastructure, regulatory nuance, and clinical adoption trends across major global regions shape practical strategies for rolling out canine cancer screening solutions

Regional dynamics shape access, reimbursement paradigms, and the practical rollout of screening programs. In the Americas, concentration of advanced diagnostic laboratories and a large base of specialty veterinary hospitals supports rapid adoption of new assays and imaging platforms, while regional regulatory frameworks and payer structures influence procurement cycles and service pricing. Transitioning from urban centers to community clinics requires attention to scalability, remote interpretation services, and point-of-care compatibility to ensure equitable access.

Europe, Middle East & Africa present heterogenous markets where regulatory complexity and variable infrastructure create both challenges and localized opportunities. Certain European markets demonstrate strong integration between academic research and clinical practice, enabling rapid evidence generation and specialty referrals, whereas other regions may prioritize low-cost, high-impact screening methods. In the Middle East and Africa, strategic partnerships and capacity-building initiatives can accelerate technology transfer and laboratory network development.

Asia-Pacific features a mix of high-volume urban veterinary services and rapidly growing specialty care, driving demand for cost-effective molecular diagnostics and flexible service models. Manufacturers and service providers targeting this region should plan for diverse regulatory environments, local language support for clinical reporting, and scalable distribution channels that accommodate both metropolitan centers and emerging markets. Across all regions, tailored commercialization strategies that align with local clinical workflows and economic realities will be critical to successful deployment.

Key competitive behaviors and strategic priorities observed among diagnostic and veterinary technology companies driving differentiation and clinical adoption

Leading companies in the diagnostic and veterinary technology space are converging on a combination of platform expansion, strategic partnerships, and service-based delivery to capture value in canine cancer screening. Market incumbents often focus on enhancing platform compatibility to support a broader assay portfolio and to reduce switching costs for laboratories. Simultaneously, a cohort of specialized diagnostics providers concentrates on high-sensitivity assays tailored to specific cancer types, aiming to become the clinical reference standard for those indications.

Partnerships with veterinary hospital networks, research institutes, and contract research organizations are common, enabling rapid clinical validation and broader sample access. Companies are also investing in data analytics and reporting tools to translate complex molecular and imaging results into clear clinical guidance for veterinarians. Finally, firms improving supply chain resilience through regional manufacturing or local distributor networks create competitive advantage by ensuring consistent reagent availability and predictable service levels for diagnostic laboratories and veterinary clinics.

Practical, high-impact recommendations for developers, laboratory operators, and service providers to accelerate adoption and sustainably scale canine cancer screening solutions

Industry leaders should prioritize a few strategic actions to translate diagnostic innovation into sustainable clinical impact. First, align product development with clinically actionable endpoints by collaborating early with veterinary oncologists and diagnostic laboratories to define performance criteria that matter in practice. Second, pursue modular platform designs and interoperable assay formats to lower integration friction for laboratories that must support heterogeneous workflows and legacy systems.

Third, invest in training and support services that reduce implementation risk for veterinary clinics and hospitals, including remote interpretation, standardized reporting templates, and client-education materials that explain screening value and follow-up pathways. Fourth, develop flexible commercial models such as reagent-as-a-service or managed diagnostic services that reduce upfront capital barriers and encourage wider adoption. Lastly, strengthen supply chain resilience through diversified sourcing and regional distribution agreements to mitigate tariff and logistics risks while preserving competitive pricing and service continuity.

A rigorous mixed-methods research approach combining systematic secondary analysis and validated primary interviews to ensure credible, practice-oriented insights

The research methodology deployed for this study combined systematic secondary analysis with structured primary research to ensure robust, reproducible insights. Secondary work included curated review of peer-reviewed literature, regulatory guidance documents, patent filings, clinical trial registries, and manufacturer technical specifications to map technology capabilities and historical performance. This desk research established the foundational taxonomy of product types, technologies, end users, cancer types, and sample modalities that informed subsequent inquiry.

Primary research comprised in-depth interviews with veterinary oncologists, diagnostic laboratory directors, veterinary hospital administrators, and R&D leaders from instrument and reagent suppliers. These interviews explored clinical workflows, validation expectations, procurement drivers, and perceived barriers to adoption. Qualitative findings were triangulated with supplier product documentation and case studies from reference laboratories to validate use cases and implementation scenarios. Where possible, methodological rigor was preserved through cross-validation across independent sources and iterative expert review to minimize bias and ensure practical relevance of conclusions.

Concluding synthesis highlighting the opportunities and practical considerations that will govern successful scale-up of canine cancer screening solutions in clinical practice

In summary, the field of canine cancer screening stands at an inflection point where technological progress, evolving clinical expectations, and shifting commercial dynamics converge to create tangible opportunities for improved early detection. Multimodal diagnostic pathways that integrate biomarker assays, genetic testing, and targeted imaging are emerging as the most promising route to enhance sensitivity and clinical utility. At the same time, practical considerations such as sample type selection, laboratory capabilities, and regional regulatory frameworks will determine the pace and breadth of adoption.

Strategic responses from manufacturers and service providers that emphasize interoperability, evidence generation, and flexible commercial models will be rewarded with broader market access and stronger clinician trust. Operational resilience-particularly in supply chains and regional distribution-remains a key determinant of sustained success. Stakeholders who prioritize clinician collaboration, transparent performance communication, and scalable implementation support will be best positioned to translate diagnostic innovation into measurable improvements in veterinary cancer outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canine Cancer Screening Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Imaging Instruments
    • 8.1.2. Molecular Instruments
    • 8.1.3. Sequencing Platforms
  • 8.2. Reagents & Kits
    • 8.2.1. Eliza Kits
    • 8.2.2. NGS Kits
    • 8.2.3. PCR Reagents
  • 8.3. Services
    • 8.3.1. Contract Research
    • 8.3.2. Laboratory Services

9. Canine Cancer Screening Market, by Technology

  • 9.1. Biomarker Assays
    • 9.1.1. Elisa
    • 9.1.2. Immunohistochemistry
  • 9.2. Genetic Testing
    • 9.2.1. PCR Based
    • 9.2.2. Sequencing Based
  • 9.3. Imaging
    • 9.3.1. CT
    • 9.3.2. MRI
    • 9.3.3. Ultrasound
    • 9.3.4. X-Ray
  • 9.4. Molecular Diagnostics
    • 9.4.1. NGS
    • 9.4.2. PCR
    • 9.4.3. QPCR

10. Canine Cancer Screening Market, by Cancer Type

  • 10.1. Hemangiosarcoma
  • 10.2. Lymphoma
  • 10.3. Mammary Tumors
  • 10.4. Skin Cancer

11. Canine Cancer Screening Market, by Sample Type

  • 11.1. Blood
  • 11.2. Fine Needle Aspirate
  • 11.3. Saliva
  • 11.4. Tissue Biopsy
  • 11.5. Urine

12. Canine Cancer Screening Market, by End User

  • 12.1. Diagnostic Laboratories
    • 12.1.1. Clinical Laboratories
    • 12.1.2. Reference Laboratories
  • 12.2. Research Institutes
    • 12.2.1. Academic Institutions
    • 12.2.2. Private Research
  • 12.3. Veterinary Clinics
    • 12.3.1. Small Animal Clinics
    • 12.3.2. Specialty Clinics
  • 12.4. Veterinary Hospitals
    • 12.4.1. Corporate Hospitals
    • 12.4.2. Independent Hospitals

13. Canine Cancer Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Canine Cancer Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Canine Cancer Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Canine Cancer Screening Market

17. China Canine Cancer Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Animal Cancer Care and Research, Inc.
  • 18.6. Anivive Lifesciences, Inc.
  • 18.7. Biomerieux SA
  • 18.8. BluePearl Veterinary Partners, LLC
  • 18.9. Cancan Diagnostics AB
  • 18.10. Cutting Edge Laser Technologies, LLC
  • 18.11. Embark Veterinary, Inc.
  • 18.12. Heska Corporation
  • 18.13. IDEXX Laboratories, Inc.
  • 18.14. LiteCure LLC
  • 18.15. Mars Petcare, Inc.
  • 18.16. Oncotect, Inc.
  • 18.17. Pathway Vet Alliance, Inc.
  • 18.18. PetDx, Inc.
  • 18.19. Petnostics Ltd.
  • 18.20. Siemens Healthineers AG
  • 18.21. Torigen Specialty Pathology, Inc.
  • 18.22. VetDC, Inc.
  • 18.23. VetGen, LLC
  • 18.24. VolitionRx Limited
  • 18.25. Wuxi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANINE CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANINE CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANINE CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELIZA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CONTRACT RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY HEMANGIOSARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY MAMMARY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SKIN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY PRIVATE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SMALL ANIMAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY CORPORATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY INDEPENDENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL CANINE CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY BIOMARKER ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN CANINE CANCER SCREENING MARKET SIZE, BY VETERINARY HOSPITALS, 2018-2032 (USD M